Literature DB >> 7181522

Early iron overload in beta-thalassaemia major: when to start chelation therapy?

S Fargion, M T Taddei, V Gabutti, A Piga, A Di Palma, L Capra, G Fontanelli, A Avanzini.   

Abstract

Twenty-eight children with beta-thalassaemia major aged between 11 and 48 months were given intensive transfusions. Serum iron, transferrin saturation, serum ferritin, non-transferrin iron, and subcutaneous desferrioxamine-induced urinary iron excretion were measured. The results showed that even children with a limited number of transfusions had severe iron overload as indicated, in particular, by the raised serum ferritin levels and the high excretion rates after subcutaneous infusion of desferrioxamine. The desferrioxamine test was useful, even in very young children, in assessing response to chelation therapy thus enabling such treatment to be started early to prevent harm from iron overload.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7181522      PMCID: PMC1628074          DOI: 10.1136/adc.57.12.929

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Microchromatography of hemoglobins. II. A simplified procedure for the determination of hemoglobin A2.

Authors:  T H Huisman; W A Schroeder; A N Brodie; S M Mayson; J Jakway
Journal:  J Lab Clin Med       Date:  1975-10

2.  A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.

Authors:  E A Letsky
Journal:  Birth Defects Orig Artic Ser       Date:  1976

3.  Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors:  R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

4.  Long-term desferrioxamine therapy in thalassemia.

Authors:  C B Modell; J Beck
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

5.  Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.

Authors:  A V Hoffbrand; A Gorman; M Laulicht; M Garidi; J Economidou; P Georgipoulou; M A Hussain; D M Flynn
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321

6.  New approaches to the transfusion management of thalassemia.

Authors:  R D Propper; L N Button; D G Nathan
Journal:  Blood       Date:  1980-01       Impact factor: 22.113

7.  Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.

Authors:  M Barry; D M Flynn; E A Letsky; R A Risdon
Journal:  Br Med J       Date:  1974-04-06

8.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

9.  Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity.

Authors:  C Hershko; G Graham; G W Bates; E A Rachmilewitz
Journal:  Br J Haematol       Date:  1978-10       Impact factor: 6.998

10.  Prevention of iron loading in transfusion-dependent thalassaemia.

Authors:  M J Pippard; E A Letsky; S T Callender; D J Weatherall
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  6 in total

Review 1.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

2.  Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients.

Authors:  Rashid H Merchant; Amruta Shirodkar; Javed Ahmed
Journal:  Indian J Pediatr       Date:  2011-01-14       Impact factor: 1.967

3.  Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

Authors:  S De Virgiliis; M Congia; M P Turco; F Frau; C Dessi; F Argiolu; R Sorcinelli; A Sitzia; A Cao
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

4.  Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy.

Authors:  Somchit Jaruratanasirikul; Rarong Chareonmuang; Malai Wongcharnchailert; Vichai Laosombat; Pasuree Sangsupavanich; Kalaya Leetanaporn
Journal:  Eur J Pediatr       Date:  2007-09-25       Impact factor: 3.183

5.  Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

Authors:  R G Grundy; K A Woods; M O Savage; J P Evans
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

Review 6.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.